SpaceJX Blank Document

SpaceJX Corp

spacejx.com

"Revolutionizing the aerospace industry with genetic engineering technology and artificial proteins"

Version: 1.1 / August 2025

⚠️ **Disclaimer**: *For informational purposes only. This is not a securities offering.*

Executive Summary

Informal Introduction: This blank document is a simplified and summarized format for conveying necessary information to our research and technology development partners and potential investors or community supporters.

SpaceJX develops advanced technologies in biotechnology, aerospace research, light processing technologies, and synthetic protein research, along with the study and technological development of DNA. This reflects the need for improvement in several areas to enable real and rational space travel. We need to evolve technologically in many areas to enable space travel, including research into energy optimization and resource use, such as the Dyson sphere.

All research and technological development must generate products that can be sold, patented, or that will somehow generate revenue for SpaceJX. Without this, there is essentially no reason for investment. Although we humans have a need to protect and perpetuate our species, investment is only rational and logical if supported by an expected return for investors.

In addition to seeking awards for research into technologies and discoveries, we also seek awards for research into technologies and discoveries.

We offer innovative investment options through SAFE, Reg CF, and direct investment. Our vision is to empower global investors to participate in early-stage, deep-tech projects with high growth potential.

Invest in the Future with a SAFE
A Simple Agreement for Future Capital (SAFE) allows visionary investors to support our mission today and receive capital in the future when we raise our next round of funding. Support our mission today through a SAFE (Simple Agreement for Future Capital) and receive capital in a future funding round—with a potential 30% conversion benefit when we raise our next Series A.

We also offer access to investment through Equity Crowdfunding, through authorized platforms and through legal and accessible means.

Problem and Opportunity

Current limitations in space exploration, biotechnology, and energy-efficient systems.
The human body's limitations in microgravity conditions make long journeys impossible, and even short ones, such as those in the "neighborhood," like traveling to Mars, can result in organ failure, excessive loss of muscle mass and bone structure, and serious vascular and heart problems, often with irreparable damage.
Propulsion limitations: for interstellar travel, we must seek technologies that use known particles and seek to unify the fields of physics. In addition to discovering uses for known particles, as well as theoretical particles, we must seek to understand and use them.
Regardless of how long it takes, we must begin. Just as the Dyson sphere is a long-term project, we can conduct research, studies, and practical applications to achieve a broader scope of energy harvesting and energy efficiency. Thus, connecting the light processor will generate light computers, which have greater energy efficiency and higher speed, overcoming the current barrier of transistor size, which has reached the maximum possible level due to size.

Market potential: Biotechnology, aerospace, and light processing sectors valued at trillions of dollars by 2040.

Increasing demand for advanced technology projects accessible to investors.
Governments and space agencies as partners and buyers of technologies that can be used for various purposes.

Biotechnology: Non-clinical research in genetic engineering models and synthetic protein studies, which could generate unimaginable advances.

Aerospace: Materials for use in spacecraft, energy optimization, and organic systems research.

Futuristic Technology: Organic processors, light processors, for next-generation computing, creation of long-term functional spacecraft, more advanced suits, and Dyson spheres through reduced-size plates for enhancement.

⚠️ **Disclaimer**: *All technologies are under development; no regulatory approval or guarantee of results is available.*

Business Model – SpaceJX

Core Concept
SpaceJX develops deep-tech solutions at the intersection of biotechnology, aerospace research, and advanced computing. Our mission is to overcome the biological and technological limitations of space travel while creating commercially viable innovations that improve life on Earth.

Revenue Streams

Patents & Licensing
Proprietary technologies in genetic engineering, synthetic proteins, aerospace materials, and photonics.
Licensing to biotech companies, aerospace manufacturers, and defense contractors.
Strategic Partnerships & Government Contracts
Collaboration with space agencies, research institutes, and governments seeking disruptive solutions in energy, health, and aerospace.

Commercial Products
Spin-offs of applied technologies:
Biotech → synthetic proteins & genetic tools.
Aerospace → advanced materials, organic life-support systems.
Futuristic computing → light processors & organic processors.

Equity Investment Platform
Innovative access to early-stage investments through:
SAFE (Simple Agreement for Future Equity) → Investors join early and receive equity with a 30% conversion benefit during Series A.
Equity Crowdfunding (Reg CF) → Broad participation from global investors in compliance with U.S. regulation.
Direct Investments (Reg D) → Accredited investors can invest larger tickets directly.

Market Opportunity
Biotechnology: Synthetic proteins, genetic engineering → multi-trillion-dollar market by 2040.

Aerospace: Materials, propulsion, and energy optimization → driven by private and governmental space exploration.
Next-Gen Computing: Light & organic processors → solving the transistor miniaturization bottleneck.

Value Proposition
For Science & Society: Pioneering research that makes interplanetary life possible while creating practical innovations for health, energy, and computing.

For Investors: Access to high-growth, deep-tech projects at early stage, with structured investment mechanisms (SAFE, Crowdfunding, Direct Equity) that balance risk with significant upside potential.

Use of Funds – SpaceJX

55% – Research & Technological Development
Core investment into biotechnology, aerospace engineering, and light processing technologies.
Focus on product development and prototypes that can be patented, licensed, or spun off into commercial ventures.
Objective: create intellectual property and sustainable revenue sources (royalties, licensing, commercialization).

15% – Marketing & Investor Relations
Building global visibility for SpaceJX's mission.
Attracting both institutional and retail investors through compliant campaigns.
Transparent communication with shareholders and the broader investor community.
Goal: expand reach, ensure trust and continuous inflow of capital.

15% – Talent & Collaborators
Recruitment and retention of top scientists, engineers, and technical specialists.
Competitive compensation and research grants to ensure long-term commitment.
Goal: maintain a world-class innovation team that drives breakthroughs.

15% – Legal, Compliance & Intellectual Property
Ensuring regulatory compliance (SEC, crowdfunding rules, international agreements).
Securing patents and protecting proprietary technologies globally.
Covering costs of corporate structure, legal audits, and defense of intellectual property.
Goal: safeguard innovation and provide legal certainty for investors.

5% – Reserve & Liquidity (Cash)
Maintained as an operational buffer for unforeseen expenses.
Ensures financial stability and risk mitigation during early-stage development.

Market and Competition – Expanded Analysis

1. TAM, SAM, SOM with Growth Projections

A. Total Addressable Market (TAM)

Genetic Engineering & Biotechnology
Valued at USD 2–8B in 2023–2024, with CAGR of 15–20%.
Broader biotechnology: USD 1.55T (2023) → USD 3.88T (2030), CAGR ~14%.

Photonics & Light-Based Processing (Light Processors)
Photonics market: USD 865B (2023), projected to USD 1.3T by 2030, CAGR ~6.5%.
Photonic processors (quantum, optical computing) are expected to disrupt AI, aerospace, and data industries.

Particle Physics & Quantum Research (Graviton, Quantum Materials)
Global quantum technology market: USD 29B (2024) → USD 106B (2030), CAGR ~24%.
Particle research (graviton studies, advanced quantum physics) is speculative but directly tied to next-generation propulsion, communication, and energy systems.

Aerospace & Space Exploration
Global aerospace market: USD 402B (2024) → USD 573B (2030), CAGR ~6%.

Space economy projected to surpass USD 1.8T by 2035 (Morgan Stanley).

Futuristic Technologies (Dyson Spheres, Organic Exo-Suits)

Emerging markets, currently R&D-focused, but linked to:

Space habitats & megastructures: early-stage, aligned with trillion-dollar space infrastructure projections post-2050.

Exo-suits & bio-augmentation: global wearable/augmented tech market at USD 61B (2024) → USD 186B (2030), CAGR ~19%.

Combined Futuristic TAM (2030 horizon): USD 5–7T+, spanning biotech, aerospace, quantum, and photonics.

B. Serviceable Available Market (SAM)
By targeting biotech + aerospace + quantum photonics niches, SpaceJX could realistically address USD 50–150B in opportunities by 2030.

C. Serviceable Obtainable Market (SOM)
For an early-stage pioneer:
Initial penetration: 0.5–1% of SAM (~USD 250M – 1B).
Scaling scenario: 2–5% of SAM by 2035 (~USD 2–7B).

2. Competitors and Differentiators
A. Competitors (by sector)
Genetic Engineering/Biotech: Thermo Fisher, CRISPR Therapeutics, Merck, GenScript.
Photonics & Quantum: Intel, IBM Quantum, PsiQuantum, Xanadu, Lightmatter.
Aerospace: SpaceX, Blue Origin, Lockheed Martin, Airbus, NASA/ESA partnerships.
Exo-Suits & Bio-Augmentation: Tesla (Neuralink adjacency), Sarcos Robotics, Boston Dynamics.

B. SpaceJX Differentiators
Interdisciplinary innovation: bridging genetic engineering, particle research, and aerospace.
Futuristic orientation: projects aligned with interplanetary survival (genetic adaptation, organic exo-suits) and energy megastructures (Dyson sphere concepts).
Niche pioneering: while incumbents dominate single verticals, SpaceJX positions itself at the intersection of biotech, aerospace, and quantum technologies.

3. Illustrative Market
Stacked Bar Chart – TAM Growth by Sector (2024 → 2030):
Biotech: USD 1.55T → 3.88T
Photonics: USD 865B → 1.3T
Quantum/Particles: USD 29B → 106B
Aerospace: USD 402B → 573B
Wearables/Exo-Suits: USD 61B → 186B

Pie Chart – SpaceJX SAM Composition (2030):
Genetic Engineering & Bio-Adaptation: 30%
Quantum/Photonics (Light Processors): 25%
Aerospace & Space Systems: 30%
Futuristic Concepts (Dyson spheres, exo-suits): 15%

Timeline – Opportunity Expansion (2025–2050):
2025–2030: Genetic engineering + photonic computing integration.
2030–2040: Interplanetary biotech, advanced propulsion research.
2040–2050: Dyson sphere concepts, organic exo-suits, post-Earth civilizations.

4. Strategic Summary
Aspect Insight
TAM (2030) USD 5–7T+ (biotech, aerospace, photonics, quantum, exo-suits)
SAM (2030) USD 50–150B
SOM (2030–2035) USD 250M–7B depending on adoption/partnerships
Competitors Big biotech (Thermo Fisher, CRISPR), quantum leaders (IBM, Lightmatter), aerospace giants (SpaceX, Airbus), robotics (Sarcos, Boston Dynamics)
Differentiators Unique fusion of biotech, aerospace, quantum, and futuristic survival technologies; vision aligned with post-planetary civilization needs

Investment Structure

1. SAFE (Simple Agreement for Future Equity)
Converts into equity during the future Series A financing round.
Conversion benefit: up to 30% discount compared to Series A share price.
Provides early investors with preferential terms and upside participation.

2. Regulation Crowdfunding (Reg CF)
Investment through registered crowdfunding portals.
Allows non-accredited investors to participate within regulatory limits.
Expands community ownership and strengthens early supporter engagement.

3. Direct Investment – Regulation D, Rule 506(c)
For accredited investors only.
General solicitation permitted under SEC rules.
Flexible investment amounts with direct allocation to the company's cap table.

4. Compliance and Investor Eligibility
All investments are subject to applicable securities laws and investor eligibility requirements.
Investor verification is required prior to participation.
The company reserves the right to accept or reject any investment at its discretion.

This creates a multi-track structure:
SAFE for simplicity and early angel investors.
Reg CF for broader community participation.
Reg D 506(c) for larger contributions from accredited investors.

Script and Milestones

Phase 1 – Seed Capital and Platform Launch
Initial fundraising.
Team building and governance structure.
Development and launch of the platform for early adopters.

Phase 2 – Research, Development and Prototyping
R&D focused on genetic engineering, photonics, and quantum technologies.
Prototyping and proof-of-concept development.
Initial testing in controlled environments.

Phase 3 – Validation, Regulation and Series A
Technical and scientific validation of solutions.
Engagement with national and international regulatory bodies.
Strategic partnerships and Series A fundraising.

⚠️ **Risks and Disclaimer**
Technical, regulatory, and market risks: uncertainties linked to the development and adoption of emerging technologies.
Forward-looking statements: subject to change depending on technological progress, market dynamics, and regulatory frameworks.
Research-stage technologies: no guarantee of technical success or financial return.
Legal disclaimer*: this document does not constitute an offer of securities. All investment opportunities are subject to applicable regulations and investor eligibility requirements.*

Team

- Founder/CEO: Alym Alves Wehrli
- CTO: Alan Wehrli
- Consultants: Globalfy

By the founder and CEO:
SpaceJX is a lifelong effort and commitment to enable our descendants to explore space and keep the human species safe. We know that the human lifespan is extremely short, a very brief period of up to 100 years, which doesn't allow for a clear vision of the future. Because seeing the past can suffer loss of information or manipulation, people generally have difficulty understanding the importance of companies like SpaceJX, which goes far beyond market capacity and the production of products and services for the current and future markets. It is also what keeps our civilization constantly moving.

I believe that through genetic engineering applied to the aerospace sector, we can enable technologies that will enable the exploration and maintenance of human life in space and other environments (exoplanets), in addition to resulting in advances in medicine and an increase in life expectancy.

I will ensure that the company's organizational culture is based on results and innovation, ensuring the optimization of resources in the form of results, good and efficient management of assets, people and money, with responsibility and efficiency.